Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Allergic Conjunctivitis

Interventions

DRUG

Bepreve (bepotastine besilate ophthalmic solution) 1.5%

sterile ophthalmic solution

DRUG

placebo comparator

sterile ophthalmic solution

DRUG

Bepotastine Besilate Ophthalmic Solution 1.0%

sterile ophthalmic solution

Trial Locations (1)

ISTA Pharmaceuticals, Inc., Irvine

All Listed Sponsors

lead

Bausch & Lomb Incorporated

INDUSTRY

NCT00586664 - Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter